Mizutani T, Kato N, Saito S, Ikeda M, Sugiyama K, Shimotohno K
Virology Division, National Cancer Research Institute, Tokyo, Japan.
J Virol. 1996 Oct;70(10):7219-23. doi: 10.1128/JVI.70.10.7219-7223.1996.
We recently found that a human T-cell leukemia virus type 1-infected cell line, MT-2, could support the replication of hepatitis C virus (HCV) (N. Kato, T. Nakazawa, T. Mizutani, and K. Shimotohno, Biochem. Biophys. Res. Commun. 206:863-869, 1995). In order to develop a culture system in which HCV replicates more efficiently, we examined the efficiency of HCV replication in cloned MT-2 cell lines by the limiting dilution method. Consequently, we obtained five clones in which intracellular positive-stranded HCV RNA could be detected until at least 21 days postinoculation (p.i.), as opposed to 15 days p.i. in uncloned MT-2 cells. MT-2C, one of the five clones which supported HCV replication up to 30 days p.i., was used for further characterization of HCV replication. Semiquantitative analysis of HCV by PCR revealed that RNA synthesis in infected cells increased after inoculation, reached a maximum level at 4 days p.i., and maintained this level until at least 11 days p.i. The 5' untranslated region of negative-stranded HCV RNA was also detected in the infected cells by two different methods with strand specificity. These results suggest that HCV replicated and multiplied in the MT-2C cells. HCV-infected MT-2C cells that were treated with antibiotics, such as G418 and hygromycin B, sustained HCV RNA for a longer period than did untreated cells. We demonstrated inhibitory effects on HCV replication by an antisense oligonucleotide complementary to the HCV core encoding region and by interferon-alpha. Furthermore, cell-free viral transmission was demonstrated by this culture system. These results suggest that our cell culture system will be useful for studying the mechanism of HCV replication, for screening antiviral agents, and for developing HCV vaccines.
我们最近发现,一株受1型人类T细胞白血病病毒感染的细胞系MT-2能够支持丙型肝炎病毒(HCV)的复制(N. Kato、T. Nakazawa、T. Mizutani和K. Shimotohno,《生物化学与生物物理研究通讯》206:863 - 869,1995年)。为了建立一个HCV能更高效复制的培养系统,我们通过有限稀释法检测了克隆的MT-2细胞系中HCV的复制效率。结果,我们获得了五个克隆,在这些克隆中,至少在接种后21天能检测到细胞内正链HCV RNA,而未克隆的MT-2细胞在接种后15天就检测不到了。MT-2C是这五个能支持HCV复制至接种后30天的克隆之一,用于进一步研究HCV复制的特性。通过PCR对HCV进行半定量分析显示,接种后感染细胞中的RNA合成增加,在接种后4天达到最高水平,并至少维持到接种后11天。通过两种具有链特异性的不同方法,在感染细胞中也检测到了负链HCV RNA的5'非翻译区。这些结果表明HCV在MT-2C细胞中进行了复制和增殖。用抗生素如G418和潮霉素B处理的HCV感染的MT-2C细胞,其HCV RNA持续存在的时间比未处理的细胞更长。我们证明了与HCV核心编码区互补的反义寡核苷酸和α干扰素对HCV复制具有抑制作用。此外,该培养系统还证明了无细胞病毒传播。这些结果表明,我们的细胞培养系统将有助于研究HCV复制机制、筛选抗病毒药物以及开发HCV疫苗。